The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
The company plans to use the technology, originally developed by Good Start Genetics, to offer sample preparation solutions and data analysis for NGS.
CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
Based on the strength of its quarterly financial performance, Invitae said it is now expecting annual revenues of between $135 million and $140 million for 2018.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
With panel sequencing data for more than 143,000 individuals, researchers characterized intragenic copy number variants in hundreds of monogenic disease genes.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.